CD4 and neoplasm: Szajnik et al. suggested that increased levels of phospho-STAT3, phospho-SMAD2/3, IL-10 and TGF-β1 expression in TEV-treated CD4+CD25hiFOXP3+ regulatory T cells (Tregs) may account for the reduced anti-tumor immune response in cancer patients [57].